Ligelizumab treatment for severe asthma: learnings from the clinical development programme.

ABSTRACT:

Objective

Ligelizumab is a humanised IgG1 anti-IgE antibody that binds IgE with higher affinity than omalizumab. Ligelizumab had greater efficacy than omalizumab on inhaled and skin allergen provocation responses in mild allergic asthma. This multi-centre, randomised, double-blind study was designed to test ligelizumab in severe asthma patients not adequately controlled with high-dose inhaled corticoids plus long-acting β2-agonist.

Methods

Patients received 16 weeks ligelizumab (240 mg q2w), omalizumab or placebo subcutaneously, and ACQ-7 was measured as primary outcome at Week 16. In addition, the study generated dose-ranging data of ligelizumab and safety data.

Results

A total of 471 patients, age 47.4 ± 13.36 years, were included in the study. Treatment with ligeli

SUBMITTER: Trischler J 

PROVIDER: S-EPMC7958305 | biostudies-literature | 2021

REPOSITORIES: biostudies-literature